Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$2.69 USD

2.69
206,356

-0.04 (-1.29%)

Updated Apr 22, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ABUS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Arbutus Biopharma Corporation [ABUS]

Reports for Purchase

Showing records 1 - 20 ( 190 total )

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

03/01/2024

Company Report

Pages: 7

4Q Recap; Expecting Three Data Readouts Around EASL 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

02/14/2024

Industry Report

Pages: 70

Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 150.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

01/11/2024

Company Report

Pages: 7

Three Data Readouts to Showcase Imdusiran in Different Combinations Against HBV; Cash Runway Out to 1Q26; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

11/08/2023

Company Report

Pages: 9

3Q Recap; AASLD Late-Breaking Presentation to Provide First Look at Imdusiran Triple Combination Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

09/12/2023

Daily Note

Pages: 3

Pipeline Updates Extend Cash Runway Out to 3Q25; Imdusiran Triple Combination Study Data on Target in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

08/04/2023

Company Report

Pages: 8

2Q Recap: New Combo Data to Inform Imdusiran''s Role in HBV Finite Therapy; NZ Medsafe Approved AB-101 CTA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

07/11/2023

Daily Note

Pages: 4

New C-Suite Appointments Bring Additional Talent to Key Positions; Expecting Multiple Milestones in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

06/22/2023

Daily Note

Pages: 5

Early AB-729/IFN Combination Data Are Encouraging; AB-729/ Immunotherapeutic Combination Data in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

05/05/2023

Company Report

Pages: 9

1Q Recap: Phase 2a AB-729 Combo Data in 2Q23 Among Three Clinical Data Readouts This Year; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

04/28/2023

Daily Note

Pages: 5

AB-729 Continues to Show Evidence As a Potential Cornerstone Treatment in HBV Functional Cure; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

04/25/2023

Daily Note

Pages: 3

AB-101 Phase 1 Study''s Initiation Delayed Due to IND Hold; Our Thesis Remains Focused on AB-729; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

04/05/2023

Daily Note

Pages: 4

Arbutus and Genevant File Patent Infringement Against Pfizer/BioNTech on Unlicensed Use of LNP Tech; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

03/20/2023

Daily Note

Pages: 4

Dosing Begins in SAD Study of RNA Destabilizer AB-161, A Potential Component of an All-Oral HBV Treatment; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

03/16/2023

Industry Report

Pages: 6

ICAR 2023: Two Presentations in Our Coverage Universe Provide Early Datasets in COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

03/03/2023

Company Report

Pages: 9

4Q Recap; Three Data Readouts in 2023 Could Inform AB-729''s Role in Finite HBV Therapy; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

12/14/2022

Daily Note

Pages: 4

Preliminary Data Confirm Consistent HBsAg Lowering Effect in Fully Enrolled AB-729, Peg-IFN Combo Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

11/10/2022

Company Report

Pages: 9

3Q Recap; AASLD Presentation Highlights AB-729''s Potential in Immunological Control; Moderating PT to $6; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

08/30/2022

Daily Note

Pages: 4

Newly Issued CoM Patent Extends AB-729''s Exclusivity to At Least April 2038; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

08/05/2022

Company Report

Pages: 14

2Q Recap; AB-729 Continues to Impress at EASL; New Phase 1 Study to Inform AB-836''s Safety; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Arbutus Biopharma Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

06/06/2022

Daily Note

Pages: 4

First Patient Dosed in Combination Study of AB-729 With VTP-300; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party